How many women have osteoporosis?J. Bone Miner. Res. 1992; 7:1005–10
Epidemiology of osteoporosis. Trends Endocrinol. Metab. 1992; 314:224–9 and , III.
www.nof.org/osteoporosis/stats.htm. Accessed March 2003
Osteoporosis: detection, prevention, and treatment in primary care. Geriatrics 1998; 53:22–33
Ethnic variation in bone turnover in pre- and early perimenopausal women: effects of anthropometric and lifestyle factors. J. Clin. Endocrinol. Metab. 2002;. 87:3051–6, , , et al.
Milk intake and bone mineral acquisition in adolescent girls: randomised, controlled intervention trial. Br. Med. J. 1997; 315:1255–60, and
Relevance of pregnancy and lactation to osteoporosis. Lancet 1998; 352:504–5
The importance of body weight history in the occurrence and recovery of osteoporosis in patients with anorexia nervosa: evaluation by dual x-ray absorptiometry and bone metabolic markers. Eur. J. Endocrinol. 1998; 139:276–83, , and
Exercise for female osteoporosis. A systematic review of randomised clinical trials. Sports Med. 1998; 25:359–68
Weight-bearing exercise training and lumbar bone mineral content in postmenopausal women. Ann. Intern. Med. 1988; 108:824–8, , , et al.
Effect of two randomized exercise programs on bone mass of healthy postmenopausal women. Br. Med. J. 1987; 295:1441–4, and
Additive effects of weight-bearing exercise and estrogen on bone mineral density in older women. J. Bone Miner. Res. 1995; 10:1303–11, , and
Effects of high-intensity strength training on multiple risk factors for osteoporotic fractures. J. Am. Med. Assoc. 1994; 272:1909–14, , , et al.
The role of exercise and fall risk reduction in the prevention of osteoporosis. Endocrinol. Metab. Clin. North Am. 1998; 27:369–87, and
Physical exercise and bone health. J. Am. Med. Womens Assoc. 1990; 45:91–97
Diagnosis of osteoporosis in clinical practice. Ann. Med. 1998; 30:278–87 and
World Health Organization. Assessment of Fracture Risk and its Application to Screening for Postmenopausal Osteoporosis: Report of a WHO Study Group. Geneva: WHO; 1994
Osteoporosis: using “bone markers” for diagnosis and monitoring. Geriatrics 1996: 51:24–30
Current state of bone densitometry for osteoporosis. Radiographics 1998; 18:913–18
Applications of bone densitometry for osteoporosis. Endocrinol. Metab. Clin. North Am. 1998; 27:267–88 and
Scientific Advisory Board, Osteoporosis Society of Canada. Clinical practice guidelines for the diagnosis and management of osteoporosis. Can. Med. Assoc. J. 1996; 155:1113–33
US Preventive Services Task Force. Guide to Clinical Preventive Services. Baltimore, MD: Williams & Wilkins; 1996
The impact of estrogen replacement therapy and raloxifene on osteoporosis, cardiovascular disease, and gynecologic cancers. Ann. Pharmacother. 1999; 33:1315–28, , and
Alendronate and estrogen–progestin in the long-term prevention of bone loss: four-year results from the early postmenopausal intervention cohort study: a randomized trial. Ann. Intern. Med. 1999; 131:935–42, , et al.
Risks and benefits of estrogen plus progestin in healthy postmenopausal women. J. Am. Med. Assoc. 2002; 288: 32–33, , , et al.
The use of estrogens and progestins and the risk of breast cancer in postmenopausal women. N. Engl. J. Med. 1995; 332:1589–93, , , et al.
The role of calcium and vitamin D in the prevention of osteoporosis. Endocrinol. Metab. Clin. North Am. 1998; 27:389–98
Calcium supplementation with and without hormone replacement therapy to prevent postmenopausal bone loss. Ann. Intern. Med. 1994; 114:97–103, , , et al.
The role of calcium and vitamin D in the prevention of osteoporosis. Endocrinol. Metab. Clin. North. Am. 1998; 27:389–98
The role of calcitonin in the prevention of osteoporosis. Endocrinol. Metab. Clin. North. Am. 1998; 27:411–18
Effect of salcatonin given intranasally on bone mass and fracture rates in established osteoporosis: a dose response study. Br. Med. J. 1992; 305:556–61, , and
Salmon-calcintonin nasal spray prevents vertebral fractures in established osteoporosis. Final world wide results of the “PROOF”. Calcif. Tissue Int. 1999; 64 (supp 1):1–26, , , et al.
Treatment of osteoporosis with bisphosphonates. Endocrinol. Metab. Clin. North. Am. 1998; 27:419–39
risk–benefit assessment of alendronate in the treatment of involutional osteoporosis. Drug Saf. 1998; 19:141–54
Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet 1996; 348:1535–41, , , et al.
Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. N. Engl. J. Med. 1998; 339: 292–9, , , et. al
Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Osteoporos. Int. 2000; 11:83–91, , , et al.
Effects of residronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis. A randomized controlled trial. J. Am. Med. Assoc. 1999; 282:1344–52, , , et al.
Therapy for fracture prevention. J. Am. Med. Assoc. 1999; 282; 687–9
Intravenous pamidonate as treatment for osteoporosis after heart transplantation: a prospective study. Osteoporos. Int. 2001; 12: 112–16, , , et al.
Effects of raloxifene on bone mineral density, serum cholesterol concentrations and uterine endometrium in postmenopausal women. N. Engl. J. Med. 1997; 337:1641–7, , , et al.
A controlled trial of raloxifene HCL: impact on bone turnover and serum lipid profile in healthy postmenopausal women. J. Bone. Miner. Res. 1996; 11:835–42, , , et al.
Raloxifene provides an alternative for osteoporosis prevention. Ann. Pharmacother. 1998; 32:834–7, and
Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene. results from a 3 year randomized clinical trial.”J. Am. Med. Assoc. 1999; 282:637–45, , , et al.
Progesterone cream for osteoporosis. Altern. Ther. Womens Health 1999; 1:33–40
Soy protein and isoflavones: their effects on blood lipids and bone density in postmenopausal women. Am. J. Clin. Nutr. 1998; 68(supp):1375–9, , , et al.
Effects of inhaled glucocorticoids on bone density in premenopausal women. N. Engl. J. Med. 1401; 345:941–7., , , et al.